Human absorption, distribution, metabolism, excretion, and reaction phenotyping of ervogastat (PF-06865571), a diacylglycerol O-acyltransferase 2 inhibitor
Drug Metabolism and Disposition · 2026-05 · 54 (5) · 100286
DOI: 10.1016/j.dmd.2026.100286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-05. Verfasst von Manoli Vourvahis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Research and Development, Pfizer Inc., New York, New York. Hauptthemen laut MEDLINE: Diacylglycerol O-Acyltransferase, Enzyme Inhibitors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
Ervogastat (PF-06865571) is a potent and selective small-molecule inhibitor of diacylglycerol-O-acyltransferase-2 currently in clinical development for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis. A fixed sequence 2-period 14C-microtracer crossover study was used to determine a comprehensive and quantitative overview of the total disposition of ervogastat after oral and intravenous administration. From these studies, ervogastat was determined to have a systemic clearance of 23.9 L/h, a volume of distribution of 38.8 L, extent of oral absorption of ∼93%, time to maximum plasma concentration of ∼3.0 hours, and absolute oral bioavailability of ∼75%. The plasma half-lives of both ervogastat and total radioactivity were similar, with no indication of long-lived metabolites. The total recovery of [14C]ervogastat after oral administration was 79.0% ± 16.7%, with 48.9% ± 16.3% in the urine and 30.1% ± 2.9% in the feces. Ervogastat metabolites observed in human plasma, urine and feces generally can be assigned as originating from 1 of 4 primary metabolic pathways: amide bond hydrolysis (M2); tetrahydrofuran oxidation (M4/M5); O-de-ethylation (M1); and direct glucuronidation (584). The major circulating drug-related components were ervogastat (43.8%), M2 (36.6%), and M6 (11.3%). The major drug-related components detected in urine were M2 (24.9%) and coeluting M6 (des-ethyl sulfate), M7 (des-ethyl amide hydrolysis) and 584 (11.4%). In the feces, the predominant drug-related products were coeluting M4 and 426 (10.0%), M2 (7.0), M7 (6.3%), and M1 (4.5%). Reaction phenotyping was carried out using a subsequent qualitative followed by quantitative approach identifying CYP3A metabolism as the predominant route of in vitro metabolism. As assignment of metabolic pathways in the hADME study was complicated by chromatographically coeluting metabolites or metabolites arising from multiple possible primary pathways, fractional clearance ranges were derived by assigning metabolites to only one primary pathway at a time to represent a potential permutation followed by evaluation of all possible permutations. This novel approach allowed us to overcome the aforementioned confounding issues and, along with in vitro chemical inhibition results, permitted the assignment of the various metabolic pathways and enzymes involved in the metabolism of ervogastat. SIGNIFICANCE STATEMENT: This study provides a comprehensive and quantitative overview of the disposition, clearance pathways, and pharmacokinetics in humans of ervogastat, a potent and selective inhibitor of diacylglycerol-O-acyltransferase-2 for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Research and Development, Pfizer Inc., New York, New York.
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc., Groton, Connecticut.
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc., Cambridge, Massachusetts.
- Clinical Bioanalytics, Research and Development, Pfizer Inc., Groton, Connecticut.
- Internal Medicine, Research and Development, Pfizer Inc., Cambridge, Massachusetts.
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc., Groton, Connecticut. Electronic address: matthew.cerny@pfizer.com.
Förderung
- Pfizer Inc
Zitieren
APA
Vourvahis, M., Orozco, C. C., Tess, D., Zhang, Y., Bauman, J. N., Gosset, J. R., Amin, N. B., & Cerny, M. A. (2026). Human absorption, distribution, metabolism, excretion, and reaction phenotyping of ervogastat (PF-06865571), a diacylglycerol O-acyltransferase 2 inhibitor. Drug Metabolism and Disposition, 54(5), 100286. https://doi.org/10.1016/j.dmd.2026.100286
Vancouver
Vourvahis M, Orozco CC, Tess D, Zhang Y, Bauman JN, Gosset JR, et al. Human absorption, distribution, metabolism, excretion, and reaction phenotyping of ervogastat (PF-06865571), a diacylglycerol O-acyltransferase 2 inhibitor. Drug Metabolism and Disposition. 2026;54(5):100286. doi:10.1016/j.dmd.2026.100286
BibTeX
@article{Vourvahis2026,
author = {Vourvahis, Manoli and Orozco, Christine C and Tess, David and Zhang, Yizhong and Bauman, Jonathan N and Gosset, James R and Amin, Neeta B and Cerny, Matthew A},
title = {Human absorption, distribution, metabolism, excretion, and reaction phenotyping of ervogastat (PF-06865571), a diacylglycerol O-acyltransferase 2 inhibitor},
journal = {Drug Metabolism and Disposition},
year = {2026},
volume = {54},
number = {5},
pages = {100286},
doi = {10.1016/j.dmd.2026.100286}
}
EUVIMED